JP Morgan Chase’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$342M Buy
385,900
+11,500
+3% +$11.7M 0.02% 508
2025
Q4
$402M Buy
374,400
+45,100
+14% +$43.1M 0.03% 458
2025
Q3
$251M Buy
329,300
+72,900
+28% +$54.2M 0.02% 617
2025
Q2
$200M Buy
256,400
+67,200
+36% +$52.2M 0.01% 684
2025
Q1
$156M Sell
189,200
-163,900
-46% -$136M 0.01% 757
2024
Q4
$273M Buy
353,100
+40,700
+13% +$33.7M 0.02% 559
2024
Q3
$277M Sell
312,400
-127,600
-29% -$115M 0.02% 571
2024
Q2
$398M Buy
440,000
+43,100
+11% +$34.5M 0.03% 420
2024
Q1
$309M Buy
396,900
+78,000
+24% +$55.5M 0.03% 518
2023
Q4
$186M Sell
318,900
-37,600
-11% -$21.9M 0.02% 633
2023
Q3
$191M Buy
356,500
+332,200
+1,367% +$171M 0.02% 562
2023
Q2
$11.4M Sell
24,300
-278,000
-92% -$117M ﹤0.01% 2188
2023
Q1
$104M Buy
302,300
+245,000
+428% +$82.6M 0.01% 779
2022
Q4
$21M Sell
57,300
-68,400
-54% -$24.3M ﹤0.01% 1636
2022
Q3
$40.6M Buy
125,700
+3,000
+2% +$951K 0.01% 1148
2022
Q2
$39.8M Sell
122,700
-185,400
-60% -$55.7M 0.01% 1171
2022
Q1
$88.2M Sell
308,100
-300,000
-49% -$77.2M 0.01% 891
2021
Q4
$168M Buy
608,100
+359,800
+145% +$91.2M 0.02% 638
2021
Q3
$57.4M Buy
248,300
+220,300
+787% +$54.4M 0.01% 1108
2021
Q2
$6.43M Buy
28,000
+3,500
+14% +$703K ﹤0.01% 2832
2021
Q1
$4.58M Buy
24,500
+20,600
+528% +$4.03M ﹤0.01% 3041
2020
Q4
$658K Sell
3,900
-38,500
-91% -$5.75M ﹤0.01% 4218
2020
Q3
$6.2M Buy
42,400
+38,500
+987% +$5.96M ﹤0.01% 2388
2020
Q2
$640K Sell
3,900
-132,100
-97% -$20.3M ﹤0.01% 3742
2020
Q1
$18.9M Buy
136,000
+60,000
+79% +$8.24M ﹤0.01% 1294
2019
Q4
$9.99M Sell
76,000
-43,000
-36% -$4.98M ﹤0.01% 2118
2019
Q3
$13.3M Buy
119,000
+18,000
+18% +$2M ﹤0.01% 1903
2019
Q2
$11.3M Sell
101,000
-2,400
-2% -$283K ﹤0.01% 2021
2019
Q1
$13.4M Sell
103,400
-38,400
-27% -$4.67M ﹤0.01% 1813
2018
Q4
$16.4M Buy
141,800
+16,600
+13% +$1.85M ﹤0.01% 1626
2018
Q3
$13.4M Buy
125,200
+2,500
+2% +$250K ﹤0.01% 1961
2018
Q2
$10.5M Buy
122,700
+17,100
+16% +$1.4M ﹤0.01% 2107
2018
Q1
$8.17M Sell
105,600
-29,500
-22% -$2.37M ﹤0.01% 2172
2017
Q4
$11.4M Buy
135,100
+87,600
+184% +$7.45M ﹤0.01% 2019
2017
Q3
$4.04M Buy
47,500
+45,200
+1,965% +$3.71M ﹤0.01% 2715
2017
Q2
$189K Sell
2,300
-690
-23% -$56.3K ﹤0.01% 3993
2017
Q1
$251K Sell
2,990
-420,600
-99% -$33.7M ﹤0.01% 3989
2016
Q4
$31.2M Buy
423,590
+272,390
+180% +$20.3M 0.01% 1185
2016
Q3
$12.1M Buy
+151,200
New +$12.1M ﹤0.01% 1660
2016
Q2
Sell
-3,232
Closed -$232K 4875
2016
Q1
$232K Buy
3,232
+3,032
+1,516% +$229K ﹤0.01% 3566
2015
Q4
$17K Hold
200
﹤0.01% 4103
2015
Q3
$17K Sell
200
-29,800
-99% -$2.52M ﹤0.01% 3842
2015
Q2
$2.5M Buy
30,000
+27,000
+900% +$2.06M ﹤0.01% 2777
2015
Q1
$218K Sell
3,000
-20,200
-87% -$1.44M ﹤0.01% 3798
2014
Q4
$1.6M Sell
23,200
-20,900
-47% -$1.41M ﹤0.01% 3086
2014
Q3
$2.86M Buy
+44,100
New +$2.79M ﹤0.01% 2703
2014
Q1
Sell
-3,200
Closed -$163K 3769
2013
Q4
$163K Sell
3,200
-6,600
-67% -$331K ﹤0.01% 3843
2013
Q3
$493K Sell
9,800
-109,800
-92% -$5.75M ﹤0.01% 3640
2013
Q2
$5.88M Buy
+119,600
New +$6.51M ﹤0.01% 2026

Other funds holding LLY

JP Morgan Chase's LLY Position: Q1 2026 in Review

JP Morgan Chase increased its Eli Lilly (LLY) stake by 5.4% in Q1 2026, buying an estimated $710M and bringing the position to 13,698,491 shares worth $12.1B. The position accounts for 0.78% of the portfolio, ranked #18.

JP Morgan Chase first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $17.1B in Q2 2024. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • JP Morgan Chase held 13,698,491 shares of Eli Lilly worth $12.1B as of Q1 2026.
  • JP Morgan Chase bought 700,545 Eli Lilly shares in Q1 2026, an estimated $710M.
  • Eli Lilly made up 0.78% of JP Morgan Chase's portfolio in Q1 2026, its #18 holding.
  • JP Morgan Chase first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • JP Morgan Chase's Eli Lilly position peaked at $17.1B in Q2 2024.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.